Drug eluting stents for symptomatic intracranial and vertebral artery stenosis.

J. D. Fields, B. D. Petersen, H. L. Lutsep, G. M. Nesbit, K. C. Liu, A. Dogan, D. S. Lee, W. M. Clark, S. L. Barnwell

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The use of bare metal stents (BMS) to prevent recurrent stroke due to stenosis of the cerebral vasculature is associated with high rates of restenosis. Drug-eluting stents (DES) may decrease this risk. We evaluated the performance of DES in a cohort of patients treated at our institution.Consecutive patients treated with DES were identified by a case log and billing records; data regarding procedural details, clinical outcome and angiographic follow-up was obtained by retrospective chart review.Twenty-six patients (27 vessels; 14 vertebral origin (VO); 13 intracranial) were treated. Stenosis was reduced from mean 81% to 8% at the VO and 80% to 2% intracranially. No strokes occurred in the first 24 hours after stenting or at any time point in the VO group during a mean follow-up period of nine months. Among patients with intracranial stents, stroke with permanent disability occurred within 30 days in 1/12 (8%) and after 30 days in 1/11 (9%) with clinical follow-up (mean follow-up, 14 months). Follow-up catheter angiography was obtained in 14/14 (100%) in the VO group at mean eight months and in 8/11 surviving patients (73%) at a mean of ten months after stenting in the intracranial group. The restenosis rate was 21% at the VO (3/14) and 38% (3/8) for intracranial stents. Restenosis at the VO was less frequent than might have been expected from reports utilizing BMS, however, overall restenosis rates appeared higher than previously reported for patients with intracranial DES and comparable with restenosis rates for intracranial BMS.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalInterventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
Volume17
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

Vertebrobasilar Insufficiency
Drug-Eluting Stents
Stents
Metals
Stroke
Pathologic Constriction
Angiography
Catheters

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Fields, J. D. ; Petersen, B. D. ; Lutsep, H. L. ; Nesbit, G. M. ; Liu, K. C. ; Dogan, A. ; Lee, D. S. ; Clark, W. M. ; Barnwell, S. L. / Drug eluting stents for symptomatic intracranial and vertebral artery stenosis. In: Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences. 2011 ; Vol. 17, No. 2. pp. 241-247.
@article{4807b66dd89f42b482e7435ac3f2b97b,
title = "Drug eluting stents for symptomatic intracranial and vertebral artery stenosis.",
abstract = "The use of bare metal stents (BMS) to prevent recurrent stroke due to stenosis of the cerebral vasculature is associated with high rates of restenosis. Drug-eluting stents (DES) may decrease this risk. We evaluated the performance of DES in a cohort of patients treated at our institution.Consecutive patients treated with DES were identified by a case log and billing records; data regarding procedural details, clinical outcome and angiographic follow-up was obtained by retrospective chart review.Twenty-six patients (27 vessels; 14 vertebral origin (VO); 13 intracranial) were treated. Stenosis was reduced from mean 81{\%} to 8{\%} at the VO and 80{\%} to 2{\%} intracranially. No strokes occurred in the first 24 hours after stenting or at any time point in the VO group during a mean follow-up period of nine months. Among patients with intracranial stents, stroke with permanent disability occurred within 30 days in 1/12 (8{\%}) and after 30 days in 1/11 (9{\%}) with clinical follow-up (mean follow-up, 14 months). Follow-up catheter angiography was obtained in 14/14 (100{\%}) in the VO group at mean eight months and in 8/11 surviving patients (73{\%}) at a mean of ten months after stenting in the intracranial group. The restenosis rate was 21{\%} at the VO (3/14) and 38{\%} (3/8) for intracranial stents. Restenosis at the VO was less frequent than might have been expected from reports utilizing BMS, however, overall restenosis rates appeared higher than previously reported for patients with intracranial DES and comparable with restenosis rates for intracranial BMS.",
author = "Fields, {J. D.} and Petersen, {B. D.} and Lutsep, {H. L.} and Nesbit, {G. M.} and Liu, {K. C.} and A. Dogan and Lee, {D. S.} and Clark, {W. M.} and Barnwell, {S. L.}",
year = "2011",
month = "6",
doi = "10.1177/159101991101700217",
language = "English (US)",
volume = "17",
pages = "241--247",
journal = "Interventional Neuroradiology",
issn = "1591-0199",
publisher = "Centauro srl",
number = "2",

}

Drug eluting stents for symptomatic intracranial and vertebral artery stenosis. / Fields, J. D.; Petersen, B. D.; Lutsep, H. L.; Nesbit, G. M.; Liu, K. C.; Dogan, A.; Lee, D. S.; Clark, W. M.; Barnwell, S. L.

In: Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, Vol. 17, No. 2, 06.2011, p. 241-247.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Drug eluting stents for symptomatic intracranial and vertebral artery stenosis.

AU - Fields, J. D.

AU - Petersen, B. D.

AU - Lutsep, H. L.

AU - Nesbit, G. M.

AU - Liu, K. C.

AU - Dogan, A.

AU - Lee, D. S.

AU - Clark, W. M.

AU - Barnwell, S. L.

PY - 2011/6

Y1 - 2011/6

N2 - The use of bare metal stents (BMS) to prevent recurrent stroke due to stenosis of the cerebral vasculature is associated with high rates of restenosis. Drug-eluting stents (DES) may decrease this risk. We evaluated the performance of DES in a cohort of patients treated at our institution.Consecutive patients treated with DES were identified by a case log and billing records; data regarding procedural details, clinical outcome and angiographic follow-up was obtained by retrospective chart review.Twenty-six patients (27 vessels; 14 vertebral origin (VO); 13 intracranial) were treated. Stenosis was reduced from mean 81% to 8% at the VO and 80% to 2% intracranially. No strokes occurred in the first 24 hours after stenting or at any time point in the VO group during a mean follow-up period of nine months. Among patients with intracranial stents, stroke with permanent disability occurred within 30 days in 1/12 (8%) and after 30 days in 1/11 (9%) with clinical follow-up (mean follow-up, 14 months). Follow-up catheter angiography was obtained in 14/14 (100%) in the VO group at mean eight months and in 8/11 surviving patients (73%) at a mean of ten months after stenting in the intracranial group. The restenosis rate was 21% at the VO (3/14) and 38% (3/8) for intracranial stents. Restenosis at the VO was less frequent than might have been expected from reports utilizing BMS, however, overall restenosis rates appeared higher than previously reported for patients with intracranial DES and comparable with restenosis rates for intracranial BMS.

AB - The use of bare metal stents (BMS) to prevent recurrent stroke due to stenosis of the cerebral vasculature is associated with high rates of restenosis. Drug-eluting stents (DES) may decrease this risk. We evaluated the performance of DES in a cohort of patients treated at our institution.Consecutive patients treated with DES were identified by a case log and billing records; data regarding procedural details, clinical outcome and angiographic follow-up was obtained by retrospective chart review.Twenty-six patients (27 vessels; 14 vertebral origin (VO); 13 intracranial) were treated. Stenosis was reduced from mean 81% to 8% at the VO and 80% to 2% intracranially. No strokes occurred in the first 24 hours after stenting or at any time point in the VO group during a mean follow-up period of nine months. Among patients with intracranial stents, stroke with permanent disability occurred within 30 days in 1/12 (8%) and after 30 days in 1/11 (9%) with clinical follow-up (mean follow-up, 14 months). Follow-up catheter angiography was obtained in 14/14 (100%) in the VO group at mean eight months and in 8/11 surviving patients (73%) at a mean of ten months after stenting in the intracranial group. The restenosis rate was 21% at the VO (3/14) and 38% (3/8) for intracranial stents. Restenosis at the VO was less frequent than might have been expected from reports utilizing BMS, however, overall restenosis rates appeared higher than previously reported for patients with intracranial DES and comparable with restenosis rates for intracranial BMS.

UR - http://www.scopus.com/inward/record.url?scp=84862833249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862833249&partnerID=8YFLogxK

U2 - 10.1177/159101991101700217

DO - 10.1177/159101991101700217

M3 - Article

C2 - 21696666

AN - SCOPUS:84862833249

VL - 17

SP - 241

EP - 247

JO - Interventional Neuroradiology

JF - Interventional Neuroradiology

SN - 1591-0199

IS - 2

ER -